Table 5_Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation.xls

Background<p>Type 2 diabetes (T2DM) combined with fatty liver is a subtype of metabolic fatty liver disease (MAFLD), and the relationship between T2DM and MAFLD is close and mutually influential. However, the connection and mechanisms between the two are still unclear. Therefore, we aimed to i...

Full description

Saved in:
Bibliographic Details
Main Author: Guiling Wu (6031019) (author)
Other Authors: Sihui Wu (20544915) (author), Tian Xiong (5563013) (author), You Yao (20625767) (author), Yu Qiu (143428) (author), Liheng Meng (11872526) (author), Cuihong Chen (10193723) (author), Xi Yang (112884) (author), Xinghuan Liang (461264) (author), Yingfen Qin (461263) (author)
Published: 2025
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1852023221125120000
author Guiling Wu (6031019)
author2 Sihui Wu (20544915)
Tian Xiong (5563013)
You Yao (20625767)
Yu Qiu (143428)
Liheng Meng (11872526)
Cuihong Chen (10193723)
Xi Yang (112884)
Xinghuan Liang (461264)
Yingfen Qin (461263)
author2_role author
author
author
author
author
author
author
author
author
author_facet Guiling Wu (6031019)
Sihui Wu (20544915)
Tian Xiong (5563013)
You Yao (20625767)
Yu Qiu (143428)
Liheng Meng (11872526)
Cuihong Chen (10193723)
Xi Yang (112884)
Xinghuan Liang (461264)
Yingfen Qin (461263)
author_role author
dc.creator.none.fl_str_mv Guiling Wu (6031019)
Sihui Wu (20544915)
Tian Xiong (5563013)
You Yao (20625767)
Yu Qiu (143428)
Liheng Meng (11872526)
Cuihong Chen (10193723)
Xi Yang (112884)
Xinghuan Liang (461264)
Yingfen Qin (461263)
dc.date.none.fl_str_mv 2025-01-28T05:10:56Z
dc.identifier.none.fl_str_mv 10.3389/fendo.2025.1512503.s003
dc.relation.none.fl_str_mv https://figshare.com/articles/dataset/Table_5_Identification_of_biomarkers_for_the_diagnosis_of_type_2_diabetes_mellitus_with_metabolic_associated_fatty_liver_disease_by_bioinformatics_analysis_and_experimental_validation_xls/28293428
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Cell Metabolism
secreted protein
metabolic associated fatty liver disease
type 2 diabetes mellitus
TNFRSF1A
SERPINB2
dc.title.none.fl_str_mv Table 5_Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation.xls
dc.type.none.fl_str_mv Dataset
info:eu-repo/semantics/publishedVersion
dataset
description Background<p>Type 2 diabetes (T2DM) combined with fatty liver is a subtype of metabolic fatty liver disease (MAFLD), and the relationship between T2DM and MAFLD is close and mutually influential. However, the connection and mechanisms between the two are still unclear. Therefore, we aimed to identify potential biomarkers for diagnosing both conditions.</p>Methods<p>We performed differential expression analysis and weighted gene correlation network analysis (WGCNA) on publicly available data on the two diseases in the Gene Expression Omnibus database to find genes related to both conditions. We utilised protein–protein interactions (PPIs), Gene Ontology, and the Kyoto Encyclopedia of Genes and Genomes to identify T2DM-associated MAFLD genes and potential mechanisms. Candidate biomarkers were screened using machine learning algorithms combined with 12 cytoHubba algorithms, and a diagnostic model for T2DM-related MAFLD was constructed and evaluated.The CIBERSORT method was used to investigate immune cell infiltration in MAFLD and the immunological significance of central genes. Finally, we collected whole blood from patients with T2DM-related MAFLD, MAFLD patients and healthy individuals, and used high-fat, high-glucose combined with high-fat cell models to verify the expression of hub genes.</p>Results<p>Differential expression analysis and WGCNA identified 354 genes in the MAFLD dataset. The differential expression analysis of the T2DM-peripheral blood mononuclear cells/liver dataset screened 91 T2DM-associated secreted proteins. PPI analysis revealed two important modules of T2DM-related pathogenic genes in MAFLD, which contained 49 nodes, suggesting their involvement in cell interaction, inflammation, and other processes. TNFSF10, SERPINB2, and TNFRSF1A were the only coexisting genes shared between MAFLD key genes and T2DM-related secreted proteins, enabling the construction of highly accurate diagnostic models for both disorders. Additionally, high-fat, high-glucose combined with high-fat cell models were successfully produced. The expression patterns of TNFRSF1A and SERPINB2 were verified in patient blood and our cellular model. Immune dysregulation was observed in MAFLD, with TNFRSF1A and SERPINB2 strongly linked to immune regulation.</p>Conclusion<p>The sensitivity and accuracy in diagnosing and predicting T2DM-associated MAFLD can be greatly improved using SERPINB2 and TNFRSF1A. These genes may significantly influence the development of T2DM-associated MAFLD, offering new diagnostic options for patients with T2DM combined with MAFLD.</p>
eu_rights_str_mv openAccess
id Manara_a4c6e547f134bdf80e609bdbfda294de
identifier_str_mv 10.3389/fendo.2025.1512503.s003
network_acronym_str Manara
network_name_str ManaraRepo
oai_identifier_str oai:figshare.com:article/28293428
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Table 5_Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation.xlsGuiling Wu (6031019)Sihui Wu (20544915)Tian Xiong (5563013)You Yao (20625767)Yu Qiu (143428)Liheng Meng (11872526)Cuihong Chen (10193723)Xi Yang (112884)Xinghuan Liang (461264)Yingfen Qin (461263)Cell Metabolismsecreted proteinmetabolic associated fatty liver diseasetype 2 diabetes mellitusTNFRSF1ASERPINB2Background<p>Type 2 diabetes (T2DM) combined with fatty liver is a subtype of metabolic fatty liver disease (MAFLD), and the relationship between T2DM and MAFLD is close and mutually influential. However, the connection and mechanisms between the two are still unclear. Therefore, we aimed to identify potential biomarkers for diagnosing both conditions.</p>Methods<p>We performed differential expression analysis and weighted gene correlation network analysis (WGCNA) on publicly available data on the two diseases in the Gene Expression Omnibus database to find genes related to both conditions. We utilised protein–protein interactions (PPIs), Gene Ontology, and the Kyoto Encyclopedia of Genes and Genomes to identify T2DM-associated MAFLD genes and potential mechanisms. Candidate biomarkers were screened using machine learning algorithms combined with 12 cytoHubba algorithms, and a diagnostic model for T2DM-related MAFLD was constructed and evaluated.The CIBERSORT method was used to investigate immune cell infiltration in MAFLD and the immunological significance of central genes. Finally, we collected whole blood from patients with T2DM-related MAFLD, MAFLD patients and healthy individuals, and used high-fat, high-glucose combined with high-fat cell models to verify the expression of hub genes.</p>Results<p>Differential expression analysis and WGCNA identified 354 genes in the MAFLD dataset. The differential expression analysis of the T2DM-peripheral blood mononuclear cells/liver dataset screened 91 T2DM-associated secreted proteins. PPI analysis revealed two important modules of T2DM-related pathogenic genes in MAFLD, which contained 49 nodes, suggesting their involvement in cell interaction, inflammation, and other processes. TNFSF10, SERPINB2, and TNFRSF1A were the only coexisting genes shared between MAFLD key genes and T2DM-related secreted proteins, enabling the construction of highly accurate diagnostic models for both disorders. Additionally, high-fat, high-glucose combined with high-fat cell models were successfully produced. The expression patterns of TNFRSF1A and SERPINB2 were verified in patient blood and our cellular model. Immune dysregulation was observed in MAFLD, with TNFRSF1A and SERPINB2 strongly linked to immune regulation.</p>Conclusion<p>The sensitivity and accuracy in diagnosing and predicting T2DM-associated MAFLD can be greatly improved using SERPINB2 and TNFRSF1A. These genes may significantly influence the development of T2DM-associated MAFLD, offering new diagnostic options for patients with T2DM combined with MAFLD.</p>2025-01-28T05:10:56ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fendo.2025.1512503.s003https://figshare.com/articles/dataset/Table_5_Identification_of_biomarkers_for_the_diagnosis_of_type_2_diabetes_mellitus_with_metabolic_associated_fatty_liver_disease_by_bioinformatics_analysis_and_experimental_validation_xls/28293428CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/282934282025-01-28T05:10:56Z
spellingShingle Table 5_Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation.xls
Guiling Wu (6031019)
Cell Metabolism
secreted protein
metabolic associated fatty liver disease
type 2 diabetes mellitus
TNFRSF1A
SERPINB2
status_str publishedVersion
title Table 5_Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation.xls
title_full Table 5_Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation.xls
title_fullStr Table 5_Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation.xls
title_full_unstemmed Table 5_Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation.xls
title_short Table 5_Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation.xls
title_sort Table 5_Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation.xls
topic Cell Metabolism
secreted protein
metabolic associated fatty liver disease
type 2 diabetes mellitus
TNFRSF1A
SERPINB2